Atai Beckley (ATAI): The Best Penny Stock to Buy and Hold Under $5

Atai Beckley Inc. (NASDAQ:ATAI) is one of the 10 Best Penny Stocks to Buy and Hold Under $5. On April 20, 2026, Canaccord ...

What’s Guggenheim Updates View on AtaiBeckley Inc (ATAI)?

AtaiBeckley Inc (NASDAQ:ATAI) is among the must-buy penny stocks to invest in now. The stock has gained more than 180% over ...

AtaiBeckley Inc.

View AtaiBeckley Inc. ATAI stock quote prices, financial information, real-time forecasts, and company news from CNN.

Psychedelic stocks rally after Trump orders faster PTSD research; Compass Pathways, Atai lead gains

Psychedelic-related stocks rose in premarket trading after President Donald Trump signed an executive order aimed at accelerating research and expanding access to substances used abroad to treat ...

H.C. Wainwright Reaffirms Their Buy Rating on Atai Beckley N.V. (ATAI)

Detailed price information for Ataibeckley Inc (ATAI-Q) from The Globe and Mail including charting and trades.
Insider Monkey

Wall Street Bullish on AtaiBeckley (ATAI), Here’s Why

AtaiBeckley Inc. (NASDAQ:ATAI) is one of the Best Penny Stocks That Will Skyrocket. Wall Street is bullish on AtaiBeckley Inc. (NASDAQ:ATAI) with analysts’ 12-month median price target reflecting more ...
Seeking Alpha

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

NEW YORK and BERLIN and OXFORD, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (ATAI) (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company on a ...
Nasdaq

atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression

NEW YORK, and AMSTERDAM and OXFORD, United Kingdom, July 01, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company on a mission to develop ...
Nasdaq

atai Life Sciences and Beckley Psytech Announce Positive Phase 2b Results for BPL-003 in Treatment-Resistant Depression

Atai Life Sciences and Beckley Psytech announced positive results from a Phase 2b clinical trial evaluating BPL-003, a treatment for treatment-resistant depression (TRD). The study achieved its ...